Nasdaq has proposed that such consolidation is impermissible under Nasdaqs general
policies, Canopy said in a filing.
Right now, companies that sell or cultivate cannabis containing THC in the US are barred from listing on major
stock exchanges like the Nasdaq.
Canopy said its in discussions with Nasdaq about the matter, and Klein said in an interview that the Canopy USA
deal was similar to the companys arrangement with another US cannabis company, TerrAscend, which he said had been vetted by Nasdaq and by Canadas TSX exchange.
We continue to have open conversations with the exchanges, Klein said. Theyre aware of our structures. Theyve seen this all
ahead of time, prior to our announcement.
Its an evolving regulatory environment, but well continue to work with both exchanges to make
sure that we comply with regulations because its important for us to remain listed.
John McKenzie, the CEO of TMX Group, the parent company
of the TSX exchange, said in an interview with BNN that Canopys plan complies with the exchanges regulations. He added that Canopys deal could provide a model for other Canadian cannabis companies that want to do business in the
US.
In a note on Thursday, Jefferies analysts said McKenzies comments could potentially help trigger more M&A for US assets, and
provide a potential pathway for US cannabis firms to list on the TSX, which could improve their access to investors.
Canopys bid to win over
Nasdaq could have huge implications for US cannabis
The success or failure of Canopys efforts to win over Nasdaq could have big implications for
the rest of the US cannabis industry.
When the deal was announced, some analysts, lawyers, and other industry experts said it could pave the way for
other cannabis companies that operate in the US to list on marquee exchanges, which would make it easier for them to raise capital.
Jefferies said
Nasdaqs objection to Canopys plan was a key risk and that the rest of the cannabis industry should pay close attention.
What is very
clear now though, is that developments here now become an absolute critical watch-out, not only for Canopy, the Jefferies analysts said in a note.
Analysts from Stifel downgraded Canopys stock to a sell rating Wednesday and said some of the nuances of the deal may allow Constellation Brands, the
Corona beer maker that backs Canopy, to wiggle out of its partnership.
Constellation Brands invested $4 billion in Canopy Growth in 2018.
If a US cannabis-reform bill that would let cannabis companies access banks passes during the upcoming lame-duck congressional session, its possible
that Canopys issues with Nasdaq will become moot, experts told Insider, though its an open question as to how the exchanges will view the protections the bill, known as the SAFE Banking Act, would provide.